Vor Bio

The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, to address serious autoantibody-driven conditions worldwide.

Telitacicept has demonstrated consistent, disease-modifying activity across autoimmune conditions, from myasthenia gravis to Sjögren’s disease and recently IgA nephropathy.